Cost-effectiveness of losartan in patients with hypertension and LVH: An economic evaluation of the LIFE trial

被引：0

作者：

Jonsson, B

Carides, GW

Burke, TA

Dasbach, EJ

Lindholm, L

Dahlof, B

机构：

[1] Stockholm Hlth Econ, Stockholm, Sweden

[2] Merck & Co Inc, Whitehouse Stn, NJ USA

[3] Umea Univ Hosp, S-90185 Umea, Sweden

[4] Sahlgrens Univ Hosp Ostra, Gothenburg, Sweden

来源：

JOURNAL OF HYPERTENSION | 2004年 / 22卷

关键词：

D O I：

10.1097/00004872-200406002-01004

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

引用

页码：S289 / S290

页数：2

共 50 条

[1] Cost-effectiveness of losartan in patients with hypertension and LVH in Spain: An economic evaluation based on the life trial
Ruilope, LM
Burke, TA
Carides, GW
Nocea, G
[J]. VALUE IN HEALTH, 2004, 7 (06) : 689 - 689
[2] Cost effectiveness of losartan in patients with hypertension and LVH:: an economic evaluation for Sweden of the LIFE trial
Jönsson, B
Carides, GW
Burke, TA
Dasbach, LJ
Lindholm, LH
Dahlöf, B
[J]. JOURNAL OF HYPERTENSION, 2005, 23 (07) : 1425 - 1431
[3] Cost-effectiveness of losartan in patients with hypertension and LVH: An economic evaluation for the Netherlands based on the LIFE-study
Boersma, C.
Carides, G. W.
Postma, M. J.
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 720 - 721
[4] Cost-effectiveness of losartan in patients with hypertension and LVH: An economic evaluation for the Netherlands based on the LIFE-study
Boersma, C
Carides, GW
Burke, TA
Postma, MJ
[J]. VALUE IN HEALTH, 2005, 8 (06) : A150 - A151
[5] Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
McInnes, G
Burke, TA
Carides, G
[J]. JOURNAL OF HUMAN HYPERTENSION, 2006, 20 (01) : 51 - 58
[6] Cost-effectiveness of losartan in patients with hypertension and left ventricular hypertrophy: cost per quality-adjusted life years gained in the LIFE trial
Jonsson, B
Carides, GW
Burke, TA
Dasbach, EJ
Lindholm, LH
Dahlof, B
[J]. EUROPEAN HEART JOURNAL, 2004, 25 : 331 - 331
[7] Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
G McInnes
T A Burke
G Carides
[J]. Journal of Human Hypertension, 2006, 20 : 51 - 58
[8] Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden
Ekman, M.
Bienfait-Beuzon, C.
Jackson, J.
[J]. JOURNAL OF HUMAN HYPERTENSION, 2008, 22 (12) : 845 - 855
[9] Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden
M Ekman
C Bienfait-Beuzon
J Jackson
[J]. Journal of Human Hypertension, 2008, 22 : 845 - 855
[10] An economic evaluation of intensive hypertension control in CKD patients: a cost-effectiveness study
Ye Seol Lee
Hae-Young Lee
Tae Hyun Kim
[J]. Clinical Hypertension, 28

← 1 2 3 4 5 →